Evaluation of 1,3-benzoxathiol-2-one derivatives as potential antifungal agents

Background: Over the last few years, fungal infections have emerged as a worrisome global public health problem. Candidiasis is a disease caused by Candida species and has been a problem worldwide mainly for immunosuppressed patients. Lately, the resistant strains and side effects have been reported as important issues for treating Candidiasis, which have to be solved by identifying new drugs. Objective: The goal of this work was to synthesize a series of 1,3-benzoxathiol-2-one derivatives, XY-benzo[d][1,3]oxathiol-2-ones, and evaluate their antifungal activity against five Candida species. Methods: In vitro Antifungal Screening Test and Minimum Inhibitory Concentration determination were performed according to CLSI protocols using Ketoconazole as reference drug. The cytotoxicity of the most active compounds was evaluated by hemolysis and MTT (Vero cells) assays. Results: Compounds 2 (XY = 6-hydroxy-5-nitro, MIC = 4-32 µg/mL) and 7 (XY = 6-acetoxy-5-nitro, MIC =16-64 µg/mL) showed good results when compared with current antifungals in CLSI values (MIC = 0.04-250 µg/mL). These compounds exhibited a safer cytotoxicity as well as a lower hemolytic profile than ketoconazole. Conclusion: Overall, the in vitro results pointed to the potential of compounds 2 and 7 as new antifungal prototypes to be further explored.